Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A
Arch Gynecol. 1982;231(4):279-87. doi: 10.1007/BF02111726.
Norethisterone acetate (NET) was administered to 11 oophorectomized women, primed with either 17-C-alkylated ethinylestradiol (EE) or the non-alkylated estrogen, estradiol valerate (E2V), to evaluate the effects on lipid metabolism. Blood samples were drawn after a period without hormonal replacement therapy and after 6 weeks on each estrogen and estrogen-progestogen combination. Serum and lipoprotein lipids were followed and an oral glucose tolerance test was performed with blood glucose and plasma insulin determinations. NET reversed the increase in serum triglycerides induced by EE and, when added to either estrogen, increased low density lipoproteins and reversed the high density lipoprotein lipid increase induced by both estrogens. The NET + EE, but not the NET + E2V combination, imparied glucose tolerance.
对11名已切除卵巢的女性给予醋酸炔诺酮（NET），这些女性之前已用17 - C - 烷基化乙炔雌二醇（EE）或非烷基化雌激素戊酸雌二醇（E2V）进行预处理，以评估其对脂质代谢的影响。在一段无激素替代治疗期后以及在每种雌激素和雌激素 - 孕激素组合治疗6周后采集血样。跟踪血清和脂蛋白脂质情况，并进行口服葡萄糖耐量试验，同时测定血糖和血浆胰岛素。NET逆转了EE诱导的血清甘油三酯升高，并且当添加到任何一种雌激素中时，会增加低密度脂蛋白，并逆转两种雌激素诱导的高密度脂蛋白脂质升高。NET + EE组合，但不是NET + E2V组合，损害了葡萄糖耐量。
